{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:43:55Z","timestamp":1792629835931,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>\n                      Parvovirus B19 (B19V) testing is often not required to release blood components. However, the European Pharmacopoeia requires that plasma pools for fractionation contain no more than 10\n                      <jats:sup>4<\/jats:sup>\n                      \u2009IU\/mL of B19V DNA. In France, pool B19 nucleic acid testing (NAT) screening was performed by \u00c9tablissement Fran\u00e7ais du Sang since 2015. Since June 2024, positive pools are broken down into individual testing, allowing for the identification and management of infected blood donations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      B19V NAT is performed in pools of 96 donations (P96) with the DPX Parvo\/hepatitis A virus assay (Roche). A P96 with a viral load &gt;10\n                      <jats:sup>4<\/jats:sup>\n                      \u2009IU\/mL B19V DNA is considered positive. All individual donations (IDs) testing reactive for B19V by ID\u2010NAT are excluded from plasma\u2010based medicinal products production, and the corresponding blood components are destroyed if not yet transfused.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From June 2024 to June 2025, 99 of 2,627,678 donations (3.7\/100,000) were B19V DNA positive. All blood components related to 90 donations were discarded. Of the remaining nine donations, 13 blood components (9 platelet concentrates [PCs] that had undergone pathogen reduction (PR) and four red blood cell [RBC] concentrates) were transfused before NAT results were obtained. Two B19V transmissions were reported in recipients (0.078\/100,000 transfusions) after transfusion of 1 PR\u2010PC and 1 RBC unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>B19V DNA testing for plasma intended for fractionation performed in blood services helps in avoiding transmissions by the related blood components, provided positive donations are detected prior to their transfusion. Delayed availability of results may result in transfusion\u2010transmitted B19V infection, which cannot prevented by current PR technology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70401","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:20:20Z","timestamp":1792628420000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of nationwide parvovirus\n                    <scp>B19 DNA<\/scp>\n                    screening and identification of transfusion\u2010transmitted infections"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0517-2138","authenticated-orcid":false,"given":"Virginie","family":"de la Taille","sequence":"first","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bacquet","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Guillet","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS), Centre Pays de la Loire  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Barday","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS), Auvergne Rh\u00f4ne Alpes  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christilla","family":"Monnier","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS), Auvergne Rh\u00f4ne Alpes  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8811-2549","authenticated-orcid":false,"given":"Guillaume","family":"Maccio","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS), la R\u00e9union  Saint Denis de la R\u00e9union France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-5808","authenticated-orcid":false,"given":"Pierre","family":"Gallian","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-7118","authenticated-orcid":false,"given":"Gr\u00e9gory","family":"Destras","sequence":"additional","affiliation":[{"name":"Institut des Agents Infectieux, Service de Virologie, Plateforme de g\u00e9nomique \u00e9pid\u00e9miologique des maladies infectieuses, H\u00f4pital de la Croix Rousse  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-3580","authenticated-orcid":false,"given":"Sophie Le","family":"Cam","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-5403","authenticated-orcid":false,"given":"Elodie","family":"Pouchol","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-568X","authenticated-orcid":false,"given":"Thierry","family":"Peyrard","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-8322","authenticated-orcid":false,"given":"Pierre","family":"Tiberghien","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"},{"name":"UMR RIGHT Universit\u00e9 Marie et Louis Pasteur, INSERM et \u00c9tablissement Fran\u00e7ais du Sang  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-0108","authenticated-orcid":false,"given":"Syria","family":"Laperche","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang (EFS)  Saint Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fmed.2018.00004","article-title":"Parvovirus B19: what is the relevance in transfusion medicine?","volume":"5","author":"Juhl D","year":"2018","journal-title":"Front Med"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2026.1819397","article-title":"Molecular and serologic analysis of linked blood donor and recipient samples to rule out transfusion\u2010transmitted parvovirus B19 infection","volume":"14","author":"Miller MJ","year":"2026","journal-title":"Front Public Health"},{"key":"e_1_2_9_4_1","volume-title":"European pharmacopoeia (Ph. Eur.)","author":"European Directorate for the Quality of Medicines and HealthCare (EDQM)","year":"2024"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/CMR.15.3.485-505.2002","article-title":"Human parvovirus B19","volume":"15","author":"Heegaard ED","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/vox.13616","article-title":"Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID\u201019 restriction in March 2020","volume":"119","author":"Drews SJ","year":"2024","journal-title":"Vox Sang"},{"key":"e_1_2_9_7_1","first-page":"168","article-title":"Comprehensive analysis of parvovirus B19 infection in blood donors: epidemiological trend and implications for transfusion safety and management strategies in Italy","volume":"23","author":"Candura F","year":"2025","journal-title":"Blood Transfus"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/trf.18032","article-title":"Parvovirus B19 rebound outbreak 2024 and implications for blood\u2010 and plasma\u2010product safety","volume":"64","author":"Farcet MR","year":"2024","journal-title":"Transfusion"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/v17040523","article-title":"Compelling increase in parvovirus B19 infections: analysis of molecular diagnostic trends (2019\u20132024)","volume":"17","author":"Liotti FM","year":"2025","journal-title":"Viruses"},{"key":"e_1_2_9_10_1","first-page":"515","article-title":"Surveillance of blood donors detects an exceptional parvovirus B19 outbreak in Switzerland in 2023\/2024","volume":"23","author":"Serricchio M","year":"2025","journal-title":"Blood Transfus"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1685035","article-title":"Comparison between metatranscriptomics and viral metagenomics, 16S, and host transcriptomics for comprehensive profiling of the respiratory microbiome and host response","volume":"16","author":"Destras G","year":"2025","journal-title":"Front Microbiol"},{"key":"e_1_2_9_12_1","unstructured":"SHoT.Serious hazards of transfusion annual report 2024. Available from:https:\/\/www.shotuk.org\/wp\u2010content\/uploads\/2025\/09\/ANNUAL\u2010SHOT\u2010REPORT\u20102024\u2010V1.2.pdf. Last accessed 15 Sep 2026."},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1017\/S0950268804002730","article-title":"Parvovirus B19 viraemia in Dutch blood donors","volume":"132","author":"Zaaijer HL","year":"2004","journal-title":"Epidemiol Infect"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1128\/JVI.78.22.12169-12178.2004","article-title":"Identification and characterization of persistent human erythrovirus infection in blood donor samples","volume":"78","author":"Candotti D","year":"2004","journal-title":"J Virol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2005-03-1053","article-title":"Persistent B19 infection in immunocompetent individuals: implications for transfusion safety","volume":"106","author":"Lefrere JJ","year":"2005","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcv.2016.09.004","article-title":"Detection of parvovirus B19 DNA in blood: viruses or DNA remnants?","volume":"84","author":"Molenaar\u2010de Backer MW","year":"2016","journal-title":"J Clin Virol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2009-06-225706","article-title":"A linked donor\u2010recipient study to evaluate parvovirus B19 transmission by blood component transfusion","volume":"114","author":"Kleinman SH","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/tme.12893","article-title":"Detection frequencies and viral load distribution of parvovirus B19 DNA in blood and plasma donations in England","volume":"32","author":"Williams S","year":"2022","journal-title":"Transfus Med"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1537-2995.2010.02780.x","article-title":"Recipients potentially infected with parvovirus B19 by red blood cell products","volume":"51","author":"Hourfar MK","year":"2011","journal-title":"Transfusion"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/j.1537-2995.2007.01443.x","article-title":"Blood donor screening for parvovirus B19 in Germany and Austria","volume":"47","author":"Schmidt M","year":"2007","journal-title":"Transfusion"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14088","article-title":"Persistent symptomatic parvovirus B19 infection with severe thrombocytopenia transmitted by red blood cell transfusion containing low parvovirus B19 DNA levels","volume":"57","author":"Nagaharu K","year":"2017","journal-title":"Transfusion"},{"key":"e_1_2_9_22_1","volume-title":"European Centre for Disease Prevention and Control Risks posed by reported increased circulation of human parvovirus B19 in the EU\/EEA \u2013 5 June 2024","year":"2024"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12985-021-01569-1","article-title":"Molecular\u2010genetic characterization of human parvovirus B19 prevalent in Kerala state, India","volume":"18","author":"Seetha D","year":"2021","journal-title":"Virol J"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","DOI":"10.1038\/srep35759","article-title":"Substitution rate and natural selection in parvovirus B19","volume":"6","author":"Stamenkovic GG","year":"2016","journal-title":"Sci Rep"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43158-y","article-title":"The epidemiological and genetic characteristics of human parvovirus B19 in patients with febrile rash illnesses in China","volume":"13","author":"Jiang H","year":"2023","journal-title":"Sci Rep"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/v17081034","article-title":"Intra\u2010host evolution during relapsing parvovirus B19 infection in immunocompromised patients","volume":"17","author":"Russcher A","year":"2025","journal-title":"Viruses"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29878","article-title":"Unexpected high incidence of parvovirus B19 nucleic acid detection in German blood donors in the winter\/spring season 2023\/2024","volume":"96","author":"Plumers R","year":"2024","journal-title":"J Med Virol"},{"key":"e_1_2_9_28_1","article-title":"An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024","volume":"29","author":"d'Humieres C","year":"2024","journal-title":"Euro Surveill"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.21.2400253","article-title":"New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023\/24","volume":"29","author":"Guillet M","year":"2024","journal-title":"Euro Surveill"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000445195","article-title":"Parvovirus B19 passive transmission by transfusion of Intercept(R) blood system\u2010treated platelet concentrate","volume":"43","author":"Gowland P","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000548745","article-title":"Parvovirus B19 infection after transfusion of a pathogen\u2010reduced platelet concentrate: a case report","volume":"53","author":"Solari D","year":"2026","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1423-0410.2012.01662.x","article-title":"Component pathogen inactivation: a critical review","volume":"104","author":"Prowse CV","year":"2013","journal-title":"Vox Sang"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1537-2995.2007.01237.x","article-title":"Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination","volume":"47","author":"Sawyer L","year":"2007","journal-title":"Transfusion"},{"key":"e_1_2_9_34_1","unstructured":"INTERCEPT\u00ae Blood System for Platelets\u2013Dual Storage (DS) Processing Set.2025. Available from:https:\/\/intercept\u2010usa.com\/wp\u2010content\/uploads\/2023\/06\/INTERCEPT\u2010Blood\u2010System\u2010for\u2010Platelets\u2010Package\u2010Insert\u2010%E2%80%93\u2010Dual\u2010Storage\u2010DS\u2010Processing\u2010Set\u2010US\u2010INT2530\u2010SPC\u201000701\u2010AW\u2010v7.0.pdf. Last accessed 15 Oct 2026."},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/vox.70199","article-title":"Pathogen\u2010reduced platelet concentrates in France: impact on the risk of transfusion\u2010transmitted infections, 2017\u20132024","volume":"121","author":"Laperche S","year":"2026","journal-title":"Vox Sang"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70401","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:20:26Z","timestamp":1792628426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":34,"alternative-id":["10.1111\/vox.70401"],"URL":"https:\/\/doi.org\/10.1111\/vox.70401","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"article-number":"vox.70401"}}